Rituximab Improves Clinical Outcomes of CAR-T Therapy for r/r B-ALL Via Sensitizing Leukemia Cells to CAR-T-Mediated Cytotoxicity and Reducing CAR-T Exhaustion

被引：2
|
作者：
Li, Yangzi [1 ]
Liu, Sining [2 ]
Cui, Qingya [3 ]
Liu, Lingling [1 ]
Li, Zheng [3 ]
Cui, Wei [3 ]
Li, Mengyun [3 ]
Zhu, Xiaming [3 ]
Kang, Liqing [4 ]
Yu, Lei [4 ]
Wu, Depei [5 ]
Tang, Xiaowen [3 ]
机构：
[1] Soochow Univ, Affifiliated Hosp 1, Suzhou, Peoples R China
[2] Soochow Univ, Affifiliated Hosp 1, Suzhou, Peoples R China
[3] Soochow Univ, Affiliated Hosp 1, Jiangsu Inst Hematol, Natl Clin Res Ctr Hematol Dis, Suzhou, Peoples R China
[4] Shanghai Unicar Therapy Biomed Technol Co Ltd, Shanghai, Peoples R China
[5] Soochow Univ, Natl Clin Res Ctr Hematol Dis, Jiangsu Inst Hematol, Collaborat Innovat Ctr Hematol,Affiliated Hosp 1, Suzhou, Peoples R China
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-184505
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [31] INHOUSE MANUFACTURING OF CAR-T CELLS: MAKING QUALITY CAR-T CELL THERAPY MORE ACCESSIBLE TO THE GENERAL PUBLIC
    Yu, Y. Jian
    CYTOTHERAPY, 2023, 25 (06) : S229 - S230
  • [32] A Novel Protease-Mediated Chimeric Antigen Receptor (CAR): "Double-Arm" CAR-T Cell System Improves Target Specificity of CAR-T Cell Therapy
    Aoyama, Satoru
    Yasuda, Shunichiro
    Watanabe, Daisuke
    Akiyama, Hiroki
    Umezawa, Yoshihiro
    Nogami, Ayako
    Miura, Osamu
    Kawamata, Norihiko
    BLOOD, 2019, 134
  • [33] Efficacy and safety of humanized CD19 CAR-T as a salvage therapy for recurrent CNSL of B-ALL following murine CD19 CAR-T cell therapy
    Li, Xin
    Liu, Mei-Jing
    Mou, Nan
    Yang, Zhen-Xing
    Wang, Jia
    Mu, Juan
    Zhu, Hai-Bo
    Deng, Qi
    ONCOLOGY LETTERS, 2021, 22 (05)
  • [34] Development of CAR-T cell therapy for B-ALL using a point-of-care approach
    Abdo, Luiza de Macedo
    Carvalho Barros, Luciana Rodrigues
    Viegas, Mariana Saldanha
    Codeco Marques, Luisa Vieira
    Ferreira, Priscila de Sousa
    Chicaybam, Leonardo
    Bonamino, Martin Hernan
    CANCER RESEARCH, 2020, 80 (16)
  • [35] CD19 CAR-T Cell Therapy in Children with Relapsed and Refractory B-ALL
    Molostova, Olga
    Shelikhova, Larisa
    Muzalevsky, Yakov
    Kazachenok, Alexey
    Khismatullina, Rimma
    Abugova, Julia
    Kurnikova, Elena
    Trakhtman, Pavel
    Pershin, Dmitry
    Zubachenko, Viktoria
    Fadeeva, Maria
    Popov, Alexander M.
    Illarionova, Olga
    Miakova, Natalia
    Litvinov, Dmitry
    Novichkova, Galina
    Maschan, Alexey
    Maschan, Michael
    BLOOD, 2021, 138
  • [36] DEVELOPMENT OF CAR-T CELL THERAPY FOR B-ALL USING A POINT-OF-CARE APPROACH
    Abdo, L.
    Viegas, M.
    Marques, L.
    Ferreira, P.
    Barros, L.
    Chicaybam, L.
    Bonamino, M.
    HUMAN GENE THERAPY, 2019, 30 (12) : A4 - A5
  • [37] Efficacy and safety of CAR-T cell therapy in B-ALL patients previously treated with blinatumomab
    Yurou Chu
    Biqi Zhou
    Rui Gao
    Miao Miao
    Huiying Qiu
    Xiaowen Tang
    Ying Wang
    Suning Chen
    Liqing Kang
    Depei Wu
    Yang Xu
    Blood Cancer Journal, 15 (1)
  • [38] Monitoring and safety of CAR-T therapy in clinical practice
    Serra Lopez-Matencio, Jose M.
    Garcia de Soria, Valle Gomez
    Gomez, Manuel
    Alanon-Plaza, Estefania
    Munoz-Calleja, Cecilia
    Castaneda, Santos
    EXPERT OPINION ON DRUG SAFETY, 2022, 21 (03) : 363 - 371
  • [39] CAR-T cells, the first pharmaceutical cell therapy
    Laurence, Arian
    TRANSFUSION AND APHERESIS SCIENCE, 2023, 62 (05)
  • [40] Scaffold-Mediated Static Transduction of T Cells for CAR-T Cell Therapy
    Agarwalla, Pritha
    Ogunnaike, Edikan A.
    Ahn, Sarah
    Ligler, Frances S.
    Dotti, Gianpietro
    Brudno, Yevgeny
    ADVANCED HEALTHCARE MATERIALS, 2020, 9 (14)
12345